Mr. Conway, age 65, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr. Conway continues to serve on the board of directors following such combination. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health and Adverra, Inc. Mr. Conway received a B.S. in accounting from Marquette University in 1976.
What is Robert E. Conway's net worth?
The estimated net worth of Robert E. Conway is at least $0.00 as of May 12th, 2021. Mr. Conway owns 347 shares of ARCA biopharma stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Conway may own. Learn More about Robert E. Conway's net worth.
How do I contact Robert E. Conway?
Has Robert E. Conway been buying or selling shares of ARCA biopharma?
Robert E. Conway has not been actively trading shares of ARCA biopharma within the last three months. Most recently, on Wednesday, May 12th, Robert E. Conway bought 69 shares of ARCA biopharma stock. The stock was acquired at an average cost of $459.36 per share, with a total value of $31,695.84. Following the completion of the transaction, the chairman now directly owns 347 shares of the company's stock, valued at $159,397.92. Learn More on Robert E. Conway's trading history.
Who are ARCA biopharma's active insiders?
Are insiders buying or selling shares of ARCA biopharma?
During the last year, ARCA biopharma insiders bought shares 6 times. They purchased a total of 3,421 shares worth more than $1,666,176.48. The most recent insider tranaction occured on August, 16th when Major Shareholder Henderson Group Plc Janus bought 40 shares worth more than $16,876.80. Insiders at ARCA biopharma own 30.9% of the company.
Learn More about insider trades at ARCA biopharma. Information on this page was last updated on 8/16/2024.